LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: An evaluation of Mp1p antigen screening for talaromycosis in HIV-infected antiretroviral therapy-naïve population in Guangdong, China.

    Gong, Dandan / Lin, Weiyin / Zhang, Huihua / Ou, Xu / Li, Liya / Guo, Pengle / He, Yaozu / Liu, Cong / Cai, Weiping / Tang, Xiaoping / Li, Linghua

    PLoS neglected tropical diseases

    2023  Volume 17, Issue 11, Page(s) e0011785

    Abstract: Background: Talaromycosis is one of the most common opportunistic infections in human immunodeficiency virus (HIV) infected patients. However, few researches have explored the prevalence in Southern China and fully assessed the value of the Mp1p antigen ...

    Abstract Background: Talaromycosis is one of the most common opportunistic infections in human immunodeficiency virus (HIV) infected patients. However, few researches have explored the prevalence in Southern China and fully assessed the value of the Mp1p antigen screening for the diagnosis of talaromycosis.
    Methodology/principal findings: We performed a cross-sectional study of HIV-infected antiretroviral therapy (ART)-naïve adult patients who were seen in 2018 at Guangzhou Eighth People's Hospital, Guangzhou Medical University. Serum samples collected from all the 784 enrolled patients were tested for Mp1p antigen using double-antibody sandwich enzyme-linked immunosorbent assay. A culture of pathogen was conducted in 350 clinically suspected patients to confirm talaromycosis. The overall prevalence of talaromycosis based on the Mp1p antigen detection was 11.4% (89/784) and peaked at 32.2% (75/233) in patients with CD4+ ≤50 Nr/μl. Logistic regression analysis found Mp1p antigen positive rate decreased with the increase in CD4+ counts (OR 0.982, 95% CI 0.977-0.987, P<0.01). The optimal cut-off point of the CD4+ count was 50 Nr/μl or less. Among the 350 patients received both fungal culture and Mp1p antigen detection, 95/350 (27.1%) patients were culture-positive for a Talaromyces marneffei, 75/350 (21.4%) patients were Mp1p antigen positive. The Mp1p antigen assay showed a good agreement to the culture of pathogen, and the sensitivity, specificity, positive predictive value, negative predictive value and kappa value was 71.6% (68/95), 97.3% (248/255), 90.7% (68/75), 90.2% (248/275), and 0.737, respectively. The screening accuracy of the Mp1p antigen assay in patients with CD4+ counts of ≤50 Nr/μl was superior to that in those with higher CD4+ counts.
    Conclusions/significance: Mp1p antigen screening can be an effective tool for more efficient diagnosis of Talaromycosis, especially in HIV/AIDS patients with low CD4+ counts. Future validation studies are needed.
    MeSH term(s) Adult ; Humans ; HIV ; Cross-Sectional Studies ; Mycoses/diagnosis ; HIV Infections/complications ; HIV Infections/drug therapy ; CD4 Lymphocyte Count
    Language English
    Publishing date 2023-11-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2429704-5
    ISSN 1935-2735 ; 1935-2735
    ISSN (online) 1935-2735
    ISSN 1935-2735
    DOI 10.1371/journal.pntd.0011785
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Transcriptome analysis of CD4

    Chen, Jingliang / He, Yaozu / Zhong, Huolin / Hu, Fengyu / Li, Yonghong / Zhang, Yeyang / Zhang, Xia / Lin, Weiyin / Li, Quanmin / Xu, Feilong / Chen, Shaozhen / Zhang, Hui / Cai, Weiping / Li, Linghua

    Virologica Sinica

    2023  Volume 38, Issue 3, Page(s) 398–408

    Abstract: Some HIV-infected individuals receiving ART develop low-level viremia (LLV), with a plasma viral load of 50-1000 copies/mL. Persistent low-level viremia is associated with subsequent virologic failure. The peripheral blood ... ...

    Abstract Some HIV-infected individuals receiving ART develop low-level viremia (LLV), with a plasma viral load of 50-1000 copies/mL. Persistent low-level viremia is associated with subsequent virologic failure. The peripheral blood CD4
    MeSH term(s) Humans ; HIV-1/genetics ; T-Lymphocytes ; Viremia/drug therapy ; HIV Infections/drug therapy ; HIV Seropositivity/drug therapy ; Viral Load ; Transcription Factors/genetics ; Gene Expression Profiling ; CD4-Positive T-Lymphocytes ; Anti-HIV Agents/pharmacology ; DNA-Binding Proteins/genetics
    Chemical Substances Transcription Factors ; Anti-HIV Agents ; CXXC5 protein, human ; DNA-Binding Proteins
    Language English
    Publishing date 2023-03-11
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1011219-4
    ISSN 1995-820X ; 1000-3223 ; 1003-5125
    ISSN (online) 1995-820X
    ISSN 1000-3223 ; 1003-5125
    DOI 10.1016/j.virs.2023.03.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Early on-treatment plasma interleukin-18 as a promising indicator for long-term virological response in patients with HIV-1 infection.

    Lin, Weiyin / Li, Liya / Guo, Pengle / He, Yaozu / He, Haolan / Li, Hong / Zhong, Huolin / Liu, Cong / Du, Peishan / Cai, Weiping / Tang, Xiaoping / Li, Linghua

    Frontiers in medicine

    2023  Volume 10, Page(s) 1170208

    Abstract: Background and aims: It is necessary to identify simple biomarkers that can efficiently predict the efficacy of long-term antiretroviral therapy (ART) against human immunodeficiency virus (HIV), especially in underdeveloped countries. We characterized ... ...

    Abstract Background and aims: It is necessary to identify simple biomarkers that can efficiently predict the efficacy of long-term antiretroviral therapy (ART) against human immunodeficiency virus (HIV), especially in underdeveloped countries. We characterized the dynamic changes in plasma interleukin-18 (IL-18) and assessed its performance as a predictor of long-term virological response.
    Methods: This was a retrospective cohort study of HIV-1-infected patients enrolled in a randomized controlled trial with a follow-up of 144  weeks of ART. Enzyme-linked immunosorbent assay was performed to evaluate plasma IL-18. Long-term virological response was defined as HIV-1 RNA <20 copies/mL at week 144.
    Results: Among the 173 enrolled patients, the long-term virological response rate was 93.1%. Patients with a long-term virological response had significantly lower levels of week 24 IL-18 than non-responders. We defined 64  pg./mL, with a maximum sum of sensitivity and specificity, as the optimal cutoff value of week 24 IL-18 level to predict long-term virological response. After adjusting for age, gender, baseline CD4+ T-cell count, baseline CD4/CD8 ratio, baseline HIV-1 RNA level, HIV-1 genotype and treatment strategy, we found that lower week 24 IL-18 level (≤64 vs. >64 pg./mL, a OR 19.10, 95% CI: 2.36-154.80) was the only independent predictor of long-term virological response.
    Conclusion: Early on-treatment plasma IL-18 could act as a promising indicator for long-term virological response in patients with HIV-1 infection. Chronic immune activation and inflammation may represent a potential mechanism; further validation is necessary.
    Language English
    Publishing date 2023-06-13
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2023.1170208
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China.

    He, Yaozu / Lin, Weiyin / Li, Hong / Gu, Fei / Zhong, Huolin / Lan, Yun / Li, Yonghong / Guo, Pengle / Hu, Fengyu / Cai, Weiping / Tang, Xiaoping / Li, Linghua

    Chinese medical journal

    2023  Volume 136, Issue 22, Page(s) 2686–2693

    Abstract: Background: Hepatitis B surface antigen (HBsAg) clearance is vital for a functional cure of hepatitis B virus (HBV) infection. However, the incidence and predictors of HBsAg seroclearance in patients co-infected with HBV and human immunodeficiency virus ...

    Abstract Background: Hepatitis B surface antigen (HBsAg) clearance is vital for a functional cure of hepatitis B virus (HBV) infection. However, the incidence and predictors of HBsAg seroclearance in patients co-infected with HBV and human immunodeficiency virus (HIV) remain largely unknown in Guangdong, China.
    Methods: Between 2009 and 2019, patients co-infected with HBV/HIV undergoing antiretroviral therapy (ART) in Guangzhou Eighth People's Hospital affiliated to Guangzhou Medical University were retrospectively reviewed with the endpoint on December 31, 2020. The incidence and risk factors for HBsAg seroclearance were evaluated using Kaplan-Meier and multivariate Cox regression analyses.
    Results: A total of 1550 HBV/HIV co-infected patients were included in the study, with the median age of 42 years and 86.0% (1333/1550) males. Further, 98.3% (1524/1550) received ART containing tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC). HBV DNA was examined in 1283 cases at the last follow-up. Over the median 4.7 years of follow-up, 8.1% (126/1550) patients achieved HBsAg seroclearance, among whom 50.8% (64/126) obtained hepatitis B surface antibody, 28.1% (137/488) acquired hepatitis B e antigen seroconversion, and 95.9% (1231/1283) undetectable HBV DNA. Compared with patients who maintained HBsAg positive, cases achieving HBsAg seroclearance showed no differences in age, gender, CD4 + T cell count, alanine aminotransferase (ALT) level, or fibrosis status; however, they presented lower HBV DNA levels, lower HBsAg levels, and higher rates of HBV genotype B at the baseline. Multivariate analysis showed that baseline HBsAg <1500 cutoff index (COI) (adjusted hazard ratio [aHR], 2.74, 95% confidence interval [95% CI]: 1.48-5.09), ALT elevation >2 × upper limit of normal during the first six months after receiving ART (aHR, 2.96, 95% CI: 1.53-5.77), and HBV genotype B (aHR, 3.73, 95% CI: 1.46-9.59) were independent predictors for HBsAg seroclearance (all P <0.01).
    Conclusions: Long-term TDF-containing ART has high anti-HBV efficacy including relatively high overall HBsAg seroclearance in HBV/HIV co-infected patients. Lower baseline HBsAg levels, HBV genotype B, and elevated ALT levels during the first six months of ART are potential predictors of HBsAg seroclearance.
    MeSH term(s) Male ; Humans ; Adult ; Hepatitis B Surface Antigens ; Hepatitis B virus/genetics ; HIV Infections/drug therapy ; HIV ; DNA, Viral ; Incidence ; Coinfection/drug therapy ; Retrospective Studies ; Tenofovir/therapeutic use ; Lamivudine/therapeutic use ; Hepatitis B, Chronic/drug therapy
    Chemical Substances Hepatitis B Surface Antigens ; DNA, Viral ; Tenofovir (99YXE507IL) ; Lamivudine (2T8Q726O95)
    Language English
    Publishing date 2023-10-25
    Publishing country China
    Document type Journal Article
    ZDB-ID 127089-8
    ISSN 2542-5641 ; 0366-6999 ; 1002-0187
    ISSN (online) 2542-5641
    ISSN 0366-6999 ; 1002-0187
    DOI 10.1097/CM9.0000000000002886
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Persistent chronic immune activation in HIV/HBV-coinfected patients after antiretroviral therapy.

    He, Yaozu / Cai, Weiping / Chen, Jingliang / Hu, Fengyu / Li, Feng / Lin, Weiyin / Li, Yonghong / Chen, Xiejie / Tang, Xiaoping / Li, Linghua

    Journal of viral hepatitis

    2021  Volume 28, Issue 10, Page(s) 1355–1361

    Abstract: We studied the characteristics of immune activation and investigated the underlying mechanisms in patients with human immunodeficiency virus-1/hepatitis B virus (HIV/HBV) coinfection after receiving HBV-active antiretroviral therapy. Forty patients with ... ...

    Abstract We studied the characteristics of immune activation and investigated the underlying mechanisms in patients with human immunodeficiency virus-1/hepatitis B virus (HIV/HBV) coinfection after receiving HBV-active antiretroviral therapy. Forty patients with HIV/HBV coinfection, 38 patients with HIV monoinfection and 20 healthy controls were enrolled. CD4
    MeSH term(s) CD4 Lymphocyte Count ; Coinfection ; HIV Infections/complications ; HIV Infections/drug therapy ; HIV-1 ; Hepatitis B virus ; Humans ; T-Lymphocytes, Regulatory
    Language English
    Publishing date 2021-08-08
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1212497-7
    ISSN 1365-2893 ; 1352-0504
    ISSN (online) 1365-2893
    ISSN 1352-0504
    DOI 10.1111/jvh.13559
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Persistently low CD4 cell counts are associated with hepatic events in HCV/HIV coinfected patients: data from the national free antiretroviral treatment program of China.

    Lin, Weiyin / Zhong, Huolin / Wen, Chunyan / He, Yaozu / Zheng, Xiaowen / Li, Hong / Chen, Xiejie / He, Haolan / Chen, Jinfeng / Chen, Lijuan / Liu, Cong / Tang, Xiaoping / Cai, Weiping / Li, Linghua

    Chinese medical journal

    2022  Volume 135, Issue 22, Page(s) 2699–2705

    Abstract: Background: Chronic liver disease has emerged as a leading cause of non-acquired immune deficiency syndrome (AIDS)-related mortality in hepatitis C virus (HCV)/human immunodeficiency virus (HIV)-coinfected patients. The relationship between CD4 cell ... ...

    Abstract Background: Chronic liver disease has emerged as a leading cause of non-acquired immune deficiency syndrome (AIDS)-related mortality in hepatitis C virus (HCV)/human immunodeficiency virus (HIV)-coinfected patients. The relationship between CD4 cell count and HIV-related opportunistic infections and tumors has been well characterized; however, it is unclear whether CD4 cell count is associated with HCV-related hepatic events.
    Methods: This observational cohort study enrolled HCV/HIV-coinfected patients from the National Free Antiretroviral Treatment Program of China from 2004 to 2019 in Guangzhou. The primary outcome was a composite of hepatic events, including cirrhosis complications, hepatocellular carcinoma (HCC), and liver-related mortality. Kaplan-Meier survival and multivariate logistic regression analyses were performed.
    Results: Among the 793 patients, 43 developed hepatic events during a median follow-up of 6.7 years, including 35 cirrhosis complications, 13 HCC cases, and 14 cases of liver-related mortality. The 5-year and 10-year cumulative incidences of hepatic events were 4.2% and 9.3%, respectively. Patients who developed hepatic events had a less satisfactory increase in CD4 cell count, lower peak CD4 (354.5 cells/μL vs. 560.0 cells/μL, P < 0.001), and lower percentage of peak CD4 > 500 cells/μL (30.2% vs. 60.7%, P < 0.001) after the initiation of antiretroviral therapy (ART) than those who did not. The cumulative incidences of hepatic events were higher in patients with lower peak CD4 levels with adjusted odds ratios of 3.96 (95% confidence interval [CI]: 1.51-10.40), 2.25 (95% CI: 0.87-5.86), and 0.98 (95% CI: 0.35-2.74) for patients with peak CD4 at <200 cells/μL, 200-350 cells/μL, and 351 to 500 cells/μL, respectively, relative to those with peak CD4 > 500 cells/μL. Peak CD4 was negatively associated with the risk of hepatic events in a dose-response manner ( P -value for trend = 0.004).
    Conclusion: Persistently low CD4 cell counts after ART are independently associated with a high risk of hepatic events in HCV/HIV-coinfected patients, highlighting the important role of immune reconstitution in improving liver outcomes.
    MeSH term(s) Humans ; Hepacivirus ; HIV ; HIV Infections/drug therapy ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/complications ; Coinfection/drug therapy ; Coinfection/complications ; Liver Neoplasms/drug therapy ; Liver Neoplasms/complications ; Hepatitis C/drug therapy ; Hepatitis C/complications ; Anti-Retroviral Agents/therapeutic use ; CD4 Lymphocyte Count ; Liver Cirrhosis/complications
    Chemical Substances Anti-Retroviral Agents
    Language English
    Publishing date 2022-11-20
    Publishing country China
    Document type Observational Study ; Journal Article
    ZDB-ID 127089-8
    ISSN 2542-5641 ; 0366-6999 ; 1002-0187
    ISSN (online) 2542-5641
    ISSN 0366-6999 ; 1002-0187
    DOI 10.1097/CM9.0000000000002502
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: A simple, feasible, efficient and safe treatment strategy of sofosbuvir/velpatasvir for chronic HCV/HIV-1 coinfected patients regardless of HCV genotypes: a multicenter, open-label study in China.

    Lin, Weiyin / Wang, Xicheng / Zhang, Jianbo / Wen, Chunyan / Kang, Wen / Mao, Lin / Yang, Jie / Dou, Yanyun / Shi, Liying / Dang, Bianli / Lan, Yun / Li, Hong / Li, Yonghong / Chen, Xiejie / He, Haolan / Xu, Min / He, Yaozu / Hu, Fengyu / Lu, Ruichao /
    Cai, Weiping / Li, Linghua

    The Lancet regional health. Western Pacific

    2023  Volume 36, Page(s) 100749

    Abstract: Background: The direct-acting antiviral agents (DAAs) have revolutionized the treatment of Hepatitis C Virus (HCV) infection. However, a simple and feasible treatment strategy with high efficacy and safety for HCV in patients coinfected with Human ... ...

    Abstract Background: The direct-acting antiviral agents (DAAs) have revolutionized the treatment of Hepatitis C Virus (HCV) infection. However, a simple and feasible treatment strategy with high efficacy and safety for HCV in patients coinfected with Human Immunodeficiency Virus (HIV) remains an unmet medical need, especially in areas with limited health resource. This study aims to assess the efficacy and safety of 12 weeks of treatment with sofosbuvir and velpatasvir in patients with chronic HCV/HIV-1 coinfection.
    Methods: We conducted a multicenter, single-arm, open-label study in China, which involved chronic HCV/HIV-1 coinfected patients who are receiving an antiretroviral regimen of a combination tablet consisting of elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide, (EVG/c/FTC/TAF) once daily. Patients with liver cirrhosis or experienced to DAAs treatment were excluded. All patients received combined sofosbuvir (400 mg) and velpatasvir (100 mg) tablet once daily for 12 weeks regardless of HCV genotype. The primary efficacy endpoint was sustained virologic response, defined as HCV RNA <15 IU/mL at 12 weeks after completion of treatment (SVR12). The primary safety endpoint was the proportion of patients who prematurely discontinued treatment because of adverse events. Safety and efficacy data were analyzed with an intention-to-treat (ITT) population (last observation carried forward) and per-protocol (PP) population. This trial is registered on ChiCTR.org.cn with number being ChiCTR1800020246.
    Findings: Of the 243 patients enrolled, 78% were male, 9% had been previously treated for HCV with interferon, and none had pre-defined cirrhosis, although 8% had Fibrosis 4 score (FIB-4) >3.25. A total of 233 patients completed 12-week post-treatment follow-up. Overall, 227/233 patients (97%) achieved SVR12: 100% (63/63) in those with HCV genotype 1, 67% (2/3) in those with genotype 2, 95% (84/88) in those with genotype 3, 99% (78/79) in those with genotype 6. Rates of SVR12 were lower among those with baseline FIB-4 >3.25 than those without (78% [14/18] vs. 99% [211/212], P < 0.001). HIV-1 suppression was not compromised. The most common adverse events were upper respiratory tract infection (5%), cough (3%), abnormal renal function (2%), abnormal liver function (2%), constipation (2%), urinary tract infection (2%) and sleep disorders (2%). No participant discontinued treatment because of adverse events or death.
    Interpretation: Twelve weeks of treatment with sofosbuvir/velpatasvir provide high rates of SVR and is well-tolerated in patients coinfected with HIV-1 and HCV regardless of HCV genotypes. Non-invasive liver fibrosis score may help to further distinguish patients at greater likelihood of a suboptimal response.
    Funding: The 13th Five Year Plan of the Ministry of Science and Technology of China for the prevention and treatment of major infectious diseases such as AIDS and viral hepatitis, the National Key Research and Development Program of China, Medical Key Discipline Program of Guangzhou-Viral Infectious Diseases (2021-2023), Basic research program on people's Livelihood Science and technology of Guangzhou, and National Natural Science Foundation of China.
    Language English
    Publishing date 2023-03-25
    Publishing country England
    Document type Journal Article
    ISSN 2666-6065
    ISSN (online) 2666-6065
    DOI 10.1016/j.lanwpc.2023.100749
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top